- Home
- ISPR vs OBIO Comparison
ISPR vs OBIO Comparison
Compare ISPR & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- OBIO
- Stock Information
- Founded
- ISPR 2019
- OBIO 2017
- Country
- ISPR United States
- OBIO United States
- Employees
- ISPR N/A
- OBIO N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- ISPR Health Care
- OBIO Health Care
- Exchange
- ISPR Nasdaq
- OBIO Nasdaq
- Market Cap
- ISPR 152.0M
- OBIO 147.8M
- IPO Year
- ISPR 2023
- OBIO N/A
- Fundamental
- Price
- ISPR $3.17
- OBIO $2.46
- Analyst Decision
- ISPR Strong Buy
- OBIO Strong Buy
- Analyst Count
- ISPR 2
- OBIO 4
- Target Price
- ISPR $10.00
- OBIO $14.00
- AVG Volume (30 Days)
- ISPR 52.5K
- OBIO 247.4K
- Earning Date
- ISPR 09-15-2025
- OBIO 11-11-2025
- Dividend Yield
- ISPR N/A
- OBIO N/A
- EPS Growth
- ISPR N/A
- OBIO N/A
- EPS
- ISPR N/A
- OBIO N/A
- Revenue
- ISPR $127,494,304.00
- OBIO $2,944,000.00
- Revenue This Year
- ISPR $61.29
- OBIO $29.26
- Revenue Next Year
- ISPR N/A
- OBIO $10.65
- P/E Ratio
- ISPR N/A
- OBIO N/A
- Revenue Growth
- ISPR N/A
- OBIO 41.61
- 52 Week Low
- ISPR $2.09
- OBIO $2.37
- 52 Week High
- ISPR $7.79
- OBIO $6.50
- Technical
- Relative Strength Index (RSI)
- ISPR 54.40
- OBIO 38.14
- Support Level
- ISPR $3.03
- OBIO $2.57
- Resistance Level
- ISPR $3.43
- OBIO $2.68
- Average True Range (ATR)
- ISPR 0.26
- OBIO 0.13
- MACD
- ISPR 0.01
- OBIO -0.02
- Stochastic Oscillator
- ISPR 28.72
- OBIO 2.04
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.